Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial

RCT (n=1,301) reports at 5-year follow-up, there was no difference in disease-free survival between docetaxel-capecitabine and the control group (including a taxane) - 90.7% vs 88.8%; HR 0.83, 95% CI 0.60 to 1.15; P =0.26.

SPS commentary:

The researchers also note that the power to demonstrate a potential significant difference between arms was lower than expected, mainly because of a lower accrual rate than anticipated.

Journal of Clinical Oncology